Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development

Open Access

Review articles summarize the best available evidence on a topic relevant to the NTD community.

Giovanni Rezza,

Affiliation Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
⨯
Scott C. Weaver

* E-mail: sweaver@utmb.edu

Affiliation Institute for Human Infections and Immunity and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America

http://orcid.org/0000-0001-8016-8556

⨯

Reader Comments (0)

Vaccine development
Is the Subject Area "Vaccine development" applicable to this article?

Thanks for your feedback.
Viral vaccines
Is the Subject Area "Viral vaccines" applicable to this article?

Thanks for your feedback.
Chikungunya infection
Is the Subject Area "Chikungunya infection" applicable to this article?

Thanks for your feedback.
Chikungunya virus
Is the Subject Area "Chikungunya virus" applicable to this article?

Thanks for your feedback.
Phase I clinical investigation
Is the Subject Area "Phase I clinical investigation" applicable to this article?

Thanks for your feedback.
Booster doses
Is the Subject Area "Booster doses" applicable to this article?

Thanks for your feedback.
Antibodies
Is the Subject Area "Antibodies" applicable to this article?

Thanks for your feedback.
Antigens
Is the Subject Area "Antigens" applicable to this article?

Thanks for your feedback.